Inclusion Criteria:  Provision of signed informed consent; Male or female, age of 18 or older; Patients with de novo or documented diagnosis of heart failure (NYHA II-IV) and clinically stabilized (considered for hospital discharge) after hospitalization because of an acute decompensated (congestive) heart failure (ADHF) event; eGFR ≥ 30 mL/min/1.73 m2 (CKD-EPI formula) at enrolment;  Exclusion Criteria:  Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product; Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor; Participation in another study with investigational drug within the 30 days preceding and during the present study; Type 1 diabetes mellitus; Symptomatic hypotension or systolic blood pressure <90 mmHg at 2 out of 3 measurements either at visit 1 or visit 2; Coronary revascularization (percutaneous coronary intervention because of STEMI or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization; Implantation of a CRT device within 12 weeks prior to enrolment or intent to implant a CRT device during 12 weeks of study observation period if indicated according to the actual guidelines [Ponikowski P et al. 2016]; Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization; HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic obstructive cardiomyopathy or uncorrected primary valvular disease; Symptomatic bradycardia or second or third degree heart block without a pacemaker; Severe (eGFR < 20 mL/min/1.73 m2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization; Women who are pregnant or breast feeding; Intention to become pregnant during the course of the study; Known or suspected non-compliance, drug or alcohol abuse; Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant; Patients with severely restricted liver function; Patients with recurrent mycotic genital infections;